Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Biocon

Next Previous
X
Search
Drug Profile

Trastuzumab biosimilar - Biocon

Alternative Names: BISINTEX; Bmab-200; CANHERA; CANMAb; Hercules-Viatris; HerMyl 1401O; Hertraz; HERZEMAB; MABTIN; MYL 1401O; Ogivri; PRIUNTA; TRASTUGET; trastuzumab-dkst; TUZEPTA; Zedora

Latest Information Update: 13 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon; Mylan
  • Developer Abdi Ibrahim Remede Pharma; Biocon; Libbs Farmaceutica; Viatris Inc
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 08 Feb 2024 Biocon Biologics enters into distribution agreement with Sandoz to distribute Trastuzumab biosimilar in Australia
  • 03 Aug 2023 Launched for Gastric cancer (Metastatic disease) in Poland, Netherlands, Austria, Ireland, Israel, Australia, Germany, Switzerland, Spain, Portugal, France, Czech Republic, Sweden (IV) (Biocon website, August 2023)
  • 03 Aug 2023 Launched for HER2-positive-breast-cancer (Metastatic disease) in Sweden, Czech Republic, France, Portugal, Spain, Switzerland, Germany, Israel, Ireland, Austria, Netherlands, Poland (IV) (Biocon website, August 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top